Form 4: Dexcom Executive Sells Shares to Cover Tax Obligations

Dexcom's EVP, Chief Operating Officer, Jacob Steven Leach, sold 744 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Jacob Steven Leach, EVP and Chief Operating Officer of Dexcom Inc., sold 744 shares of common stock on December 16, 2024, at a price of $76.87 per share.
• This sale was not a discretionary trade but was mandated by Dexcom's equity incentive plan to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• Following the transaction, Mr. Leach directly owns 264,171 shares of Dexcom common stock, which includes 51,972 unvested RSUs.
• These unvested RSUs were granted on March 8, 2022, 2023, and 2024, and will vest through March 8, 2025, 2026, and 2027 respectively.
• Mr. Leach also indirectly owns 47,296 shares through a family trust.

Sentiment

Score: 5

Explanation: This is a neutral event, a routine transaction for tax purposes, and does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when RSUs vest.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across publicly traded companies.
• The number of shares sold and the price are not unusual for a company of Dexcom's size and executive compensation structure.
• Similar transactions can be observed in filings from other medical device companies such as Medtronic and Abbott.

Stakeholder Impact

• The sale has a minimal impact on shareholders as it is a small transaction related to tax obligations.
• The transaction does not affect employees, customers, suppliers, or creditors.

Key Dates

Keywords

Dexcom, stock sale, insider trading, executive, restricted stock units, tax obligations, equity incentive plan